Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 22, 2008

View Archived Issues

GlaxoSmithKline full year 2007

New agents for treating endocrine-related disorders disclosed in recent patent literature

Novel treatment options for HIV infection reported by Mintaka

No viral resistance to R-7128 seen in HCV genotype 1 patients

Antiangiogenic gene therapy potentially useful for metastatic renal cell carcinoma

Perlegen and SC Liver Research Consortium to collaborate on interferon response in HCV

NeuroHealing initiates phase II clinical trial of NH-004 for sialorrhea in PD patients

ActivBiotics to conduct clinical trial to compare rifalazil and azithromycin in Chlamydia

Recordati is granted Australian approval for Zan-Extra for hypertension

Association between GVAX-induced immune responses and survival in patients with prostate cancer

New compounds for treating pain and other inflammatory conditions described in recent patents

Proteomic analysis identifies new potential targets for multiple sclerosis

Novel human monoclonal antibody against Hendra and Nipah viruses discovered

Addrenex files NDA for CloniBID for the treatment of hypertension

ConjuChem initiates phase II PC-DAC:Exendin-4 study

Glenmark's GRC-4039 enters phase I trials in rheumatoid arthritis

Millennium expands Velcade for injection program in non-Hodgkin's lymphoma

VaxGen encourages stockholders to vote in favor of the merger

Sciele Pharma launches LifeCycle Pharma's cholesterol-lowering Fenoglide in the U.S.

FDA Advisory Committee recommends Rotarix oral rotavirus vaccine for infants

Lilly receives positive opinion from the EMEA for Forsteo in GIO

FDA approves Wyeth's Xyntha for hemophilia A therapy

Antisoma commences phase I clinical study of AS-1409 in renal cancer and melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...